Akebia Therapeutics Q3 2026 Results: Net Loss of $14.4M
Akebia Therapeutics continues to face significant financial risks, including a history of losses and the need for substantial additional capital to fund operations. The company's business remains heavily dependent on the commercial success of Auryxia and Vafseo, while facing potential delisting from Nasdaq if compliance requirements are not met.
- Key figure
- Net loss $14.4M